BEKE-W
02423
JD HEALTH
06618
TME-SW
01698
JD-SW
09618
NTES-S
09999
(FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q9)Sep 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | ---- | ---- | ---- | 106.36%229.31M | ---- | -3,204.60%-3.6B | ---- | -15.85%-109.06M | -100.99%-115.88M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | ---- | ---- | ---- | ---57.53M | ---- | ---- | ---- | ---- | ---- |
Investment loss (gain) | ---- | ---- | ---- | ---- | 59.82%-22.13M | ---- | -445.64%-55.08M | ---- | 45.71%-10.1M | -9.44%-17.52M |
Attributable subsidiary (profit) loss | ---- | ---- | ---- | ---- | 145.41%99K | ---- | ---218K | ---- | ---- | ---- |
Impairment and provisions: | ---- | ---- | ---- | ---- | -69.93%83K | ---- | -46.62%276K | ---- | -88.30%517K | -85.63%555K |
-Other impairments and provisions | ---- | ---- | ---- | ---- | -69.93%83K | ---- | -46.62%276K | ---- | -88.30%517K | -85.63%555K |
Revaluation surplus: | ---- | ---- | ---- | ---- | -101.13%-41.33M | ---- | 2,676.75%3.67B | ---- | 73.18%132.26M | 101.03%93.07M |
-Other fair value changes | ---- | ---- | ---- | ---- | -101.13%-41.33M | ---- | 2,676.75%3.67B | ---- | 73.18%132.26M | 101.03%93.07M |
Asset sale loss (gain): | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.56M | ---- |
-Loss (gain) from selling other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.56M | ---- |
Depreciation and amortization: | ---- | ---- | ---- | ---- | 1.76%85.81M | ---- | 8.32%84.32M | ---- | 14.80%77.84M | 16.01%55.21M |
-Amortization of intangible assets | ---- | ---- | ---- | ---- | 333.85%9.55M | ---- | 68.66%2.2M | ---- | 199.31%1.31M | 245.23%832K |
Financial expense | ---- | ---- | ---- | ---- | 50.77%12.98M | ---- | -20.68%8.61M | ---- | -3.61%10.85M | 8.28%8.94M |
Exchange Loss (gain) | ---- | ---- | ---- | ---- | -125.07%-24.5M | ---- | 12,394.76%97.71M | ---- | --782K | --701K |
Special items | ---- | ---- | ---- | ---- | 5.70%56.22M | ---- | 203.95%53.19M | ---- | -51.09%17.5M | -7.09%28.16M |
Operating profit before the change of operating capital | ---- | ---- | ---- | ---- | -7.12%238.99M | ---- | 110.66%257.32M | ---- | 47.36%122.15M | -15.02%53.24M |
Change of operating capital | ||||||||||
Accounts receivable (increase)decrease | ---- | ---- | ---- | ---- | -40,013.36%-111.11M | ---- | -101.76%-277K | ---- | 133.00%15.76M | 130.58%35.81M |
Accounts payable increase (decrease) | ---- | ---- | ---- | ---- | 52.76%285.28M | ---- | 489.76%186.75M | ---- | -55.25%31.67M | -123.12%-16.26M |
prepayments (increase)decrease | ---- | ---- | ---- | ---- | 26.62%-118.78M | ---- | -543.83%-161.86M | ---- | 271.14%36.47M | 205.63%25.43M |
Special items for working capital changes | ---- | ---- | ---- | ---- | 148.03%8.07M | ---- | ---16.8M | ---- | ---- | ---- |
Cash from business operations | ---- | -17.47%-116.33M | ---- | 3.32%-99.03M | 14.07%302.45M | -208.66%-102.43M | 28.68%265.14M | 252.29%94.27M | 143.55%206.04M | 1,296.48%98.22M |
Other taxs | ---- | ---10.34M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Special items of business | -10.73%302.78M | ---- | --339.16M | ---- | ---- | ---- | ---- | ---- | 112.59%2.72M | 222.28%719K |
Net cash from operations | -10.73%302.78M | -27.92%-126.67M | 12.14%339.16M | 3.32%-99.03M | 14.07%302.45M | -208.66%-102.43M | 27.01%265.14M | 204.54%94.27M | 231.44%208.76M | 1,224.68%98.94M |
Cash flow from investment activities | ||||||||||
Restricted cash (increase) decrease | ---- | -49.62%5.6M | ---- | -83.36%11.12M | 179.83%66.17M | 156.80%66.78M | ---82.88M | ---117.57M | ---- | ---- |
Decrease in deposits (increase) | ---- | 190.33%170.39M | ---- | 87.37%-188.63M | -866.96%-1.91B | ---1.49B | ---197.9M | ---- | ---- | ---- |
Purchase of fixed assets | ---- | -188.93%-35.01M | ---- | 19.72%-12.12M | -15.36%-23.63M | -68.05%-15.09M | -42.34%-20.49M | -3.34%-8.98M | 63.72%-14.39M | 56.61%-10.44M |
Purchase of intangible assets | ---- | 3.91%-1.38M | ---- | -444.87%-1.43M | -31.02%-832K | -93.38%-263K | 84.05%-635K | 95.40%-136K | -5.35%-3.98M | -19.02%-3.7M |
Acquisition of subsidiaries | ---- | ---- | ---- | ---- | 62.10%-29.99M | ---29.99M | ---79.14M | ---- | ---- | ---- |
Recovery of cash from investments | ---- | 22.33%1.69B | ---- | 27.60%1.38B | -45.27%3.86B | -70.36%1.08B | 9.55%7.05B | 0.41%3.66B | -15.07%6.44B | -9.71%5.33B |
Cash on investment | ---- | -30.18%-1.81B | ---- | 12.08%-1.39B | 30.77%-4.52B | 59.89%-1.59B | 2.11%-6.53B | -5.85%-3.95B | 11.86%-6.67B | 1.69%-5.48B |
Other items in the investment business | 176.71%30.12M | ---- | ---39.27M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Net cash from investment operations | 176.71%30.12M | 108.79%17.7M | 98.47%-39.27M | 89.80%-201.29M | -1,916.74%-2.56B | -368.92%-1.97B | 156.04%141.1M | -311.43%-420.81M | -691.97%-251.78M | -150.43%-156.5M |
Net cash before financing | 11.01%332.91M | 63.72%-108.97M | 113.26%299.89M | 85.53%-300.32M | -656.55%-2.26B | -535.65%-2.08B | 1,044.38%406.24M | -357.81%-326.54M | -237.89%-43.02M | -119.09%-57.56M |
Cash flow from financing activities | ||||||||||
New borrowing | ---- | ---- | ---- | 350.00%45M | 350.00%45M | --10M | --10M | ---- | ---- | ---- |
Refund | ---- | -205.88%-52M | ---- | 52.78%-17M | ---51M | ---36M | ---- | ---- | ---- | ---- |
Issuing shares | ---- | 7.70%7.39M | ---- | 89.89%6.86M | -99.84%5M | -99.89%3.61M | --3.2B | --3.22B | ---- | ---- |
Interest paid - financing | ---- | 64.13%-1.82M | ---- | -43.75%-5.06M | -1,143.69%-8.77M | ---3.52M | ---705K | ---- | ---- | ---- |
Issuance expenses and redemption of securities expenses | ---- | 42.29%-63.94M | ---- | -122.78%-110.81M | 15.66%-123.96M | 22.35%-49.74M | ---146.97M | ---64.06M | ---- | ---- |
Other items of the financing business | -73.23%-468.9M | -3.23%-31.48M | -851.49%-270.68M | -7.72%-30.49M | -375.24%-28.45M | ---28.31M | ---5.99M | ---- | ---- | ---- |
Net cash from financing operations | -73.23%-468.9M | -24.17%-176.6M | -22.15%-270.68M | -7.26%-142.22M | -107.40%-221.59M | -104.25%-132.59M | 4,697.23%3B | 9,823.80%3.12B | 29.65%-65.17M | 36.13%-48.65M |
Effect of rate | 110.71%400K | 25.67%-1.23M | -115.25%-3.74M | -105.40%-1.65M | 125.07%24.5M | 155.34%30.6M | -12,394.76%-97.71M | ---55.29M | ---782K | ---701K |
Net Cash | -565.51%-136M | 35.47%-285.57M | 101.18%29.21M | 79.96%-442.54M | -172.97%-2.48B | -179.02%-2.21B | 3,244.81%3.4B | 2,802.13%2.79B | -76.09%-108.19M | -147.12%-106.21M |
Begining period cash | 2.87%913.99M | 2.87%913.99M | -73.45%888.51M | -73.45%888.51M | 7,877.51%3.35B | 7,877.51%3.35B | -72.20%41.95M | -72.20%41.95M | -28.93%150.92M | -28.93%150.92M |
Cash at the end | -14.84%778.39M | 41.16%627.19M | 2.87%913.99M | -61.99%444.32M | -73.45%888.51M | -57.98%1.17B | 7,877.51%3.35B | 5,756.61%2.78B | -72.20%41.95M | -89.95%44.01M |
Cash balance analysis | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Unlock the Full List